-
Ridaforolimus and the Next Wave of Senolytic Discovery
2026-08-27
Ridaforolimus, also known as Deforolimus or MK-8669, offers translational researchers a precise way to interrogate mTOR-dependent growth, metabolism, angiogenesis, and survival. Paired with machine-learning-guided senolytic discovery, it can help distinguish pathway suppression from selective senescent-cell elimination while strengthening biomarker-driven experimental design.
-
Cy3-dCTP Workflows for Direct DNA Labeling
2026-08-26
Cy3-dCTP enables direct fluorescent labeling during PCR, reverse transcription, and Nick Translation without a separate dye-coupling step. This guide combines practical probe-generation workflows with a cautious translation of DNA-framework research into assay-design decisions.
-
Antiseptics for Burns: Evidence from a Cochrane Review
2026-08-26
This Cochrane review evaluated whether topical antiseptics improve healing, prevent infection, or reduce harm in people with burns. Its main contribution was a structured synthesis showing that comparisons were heterogeneous and evidence certainty was generally low, limiting confident claims that one antiseptic strategy is superior.
-
Erlotinib Workflows for EGFR Research
2026-08-25
Build reproducible EGFR phosphorylation, proliferation, and apoptosis experiments with Erlotinib (NSC 718781). This guide also shows how to use EGFR blockade as a mechanistic comparator when studying SCUBE3-driven oncogenic signaling and immune suppression.
-
Belinostat (PXD101) Cancer Assay Workflow
2026-08-25
Build a more informative Belinostat workflow by separating growth arrest from cell killing across bladder and prostate cancer models. This practical guide combines HDAC biology, dose–response design, orthogonal readouts, formulation control, and troubleshooting for reproducible preclinical studies.
-
BIRB 796 (Doramapimod) for Reliable Assays
2026-08-24
This scenario-based guide shows how BIRB 796 (Doramapimod), SKU A5639, can support interpretable viability, apoptosis, and cytokine experiments through selective p38α MAPK inhibition. It covers controls, solvent handling, dose optimization, mechanistic interpretation, and practical vendor-selection criteria.
-
HyperFluor™ 594 Goat Anti-Rabbit IgG: Assay Design
2026-08-24
Learn how a goat anti-rabbit IgG secondary antibody can translate causal atherosclerosis evidence into rigorous imaging, tissue, flow cytometry, and ELISA workflows. This guide connects ISG20 validation, spectral planning, controls, and application-specific optimization.
-
MDV3100: AR Heterogeneity in CRPC Models
2026-08-23
MDV3100 (Enzalutamide) is a powerful tool for investigating androgen receptor dependence in prostate cancer. This article presents an AR-state-aware framework for interpreting apoptosis, resistance, and treatment-response assays in castration-resistant prostate cancer models.
-
AL-8810: Prostaglandin F2α Antagonist Workflow
2026-08-22
AL-8810 enables controlled dissection of FP receptor signaling across endometrial, vascular, smooth muscle, fibroblast, and ocular cell models. This practical guide combines potency-aware dosing, pathway-specific readouts, and troubleshooting strategies for reproducible prostaglandin F2α antagonist research.
-
IAM-LC vs LEKC for Pulmonary Drug Permeability
2026-08-22
A 2024 Journal of Chromatography A study provides the first direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug–membrane partitioning and pulmonary permeability assessment. LEKC more closely modeled apparent lung permeability, whereas IAM LC offered broader compound coverage, simpler implementation, and stronger suitability for high-throughput screening.
-
Trelagliptin and Adipocyte Insulin Resistance
2026-08-21
The reference study uses differentiated 3T3-L1 adipocytes to connect trelagliptin succinate with improved glucose uptake, GLUT4 membrane localization, and PI-3K/AKT/IRS-1 signaling. Its findings support a cellular mechanism for improved insulin sensitivity while also highlighting the limits of inferring therapeutic effects from an in vitro adipocyte model.
-
Ceftazidime Workflow for Gram-Negative Research
2026-08-20
Ceftazidime provides a practical phenotype-first tool for studying Pseudomonas aeruginosa, β-lactamase-producing Enterobacteriaceae, and resistance transmission. This workflow combines reproducible susceptibility testing with plasmid localization, conjugation, and genotype–phenotype troubleshooting.
-
Methylprednisolone: From Inflammation to Bone
2026-08-20
Methylprednisolone is a synthetic glucocorticoid receptor agonist that connects cytokine control with steroid-induced skeletal injury models. This article presents a decision framework for selecting assays, interpreting bone outcomes, and translating glucocorticoid exposure into reproducible research questions.
-
Dovitinib and the Next Wave of Translational Oncology
2026-08-19
Dovitinib (TKI-258) offers translational researchers a powerful way to interrogate convergent RTK signaling, apoptosis, and tumor-context dependencies. This thought-leadership guide connects its multitarget pharmacology with practical validation strategies, multiple myeloma research, hepatocellular carcinoma treatment research, and a cautious framework for exploring immune-related biology.
-
BIRB 796 for p38α MAPK Research
2026-08-19
BIRB 796 (Doramapimod) combines high p38α selectivity with an allosteric, slow-dissociation mechanism suited to cytokine, phospho-signaling, and apoptosis workflows. This guide translates its properties into practical assay design, control selection, and troubleshooting for inflammation research and arthritis model studies.